Business
Jaguar Health Investor Webcast Rescheduled for Wednesday, November 17th at 8:30 AM Eastern Time
Click here to register for webcastCompany plans to file Q3 2021 10-Q on November 17, 2021SAN FRANCISCO, CA / ACCESSWIRE / November 15, 2021 / Jaguar Health,
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Click here to register for webcastCompany plans to file Q3 2021 10-Q on November 17, 2021SAN FRANCISCO, CA / ACCESSWIRE / November 15, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company's investor webcast to review third-quarter 2021 financials and provide business updates will take place at 8:30 a.m. Eastern Time on Wednesday, November 17, 2021 instead of today. The date change is due to the need for additional time to finalize accounting-related aspects of the recently closed merger of Dragon SPAC S.p.A. and Napo EU S.p.A., Jaguar's majority owned Italian subsidiary.Participation Instructions for WebcastWhen: Wednesday, November 17, 2021 at 8:30 AM Eastern TimeParticipant Registration & Access Link: Click HereAbout Jaguar Health, Inc., Napo Pharmaceuticals, Inc. & Napo EU S.p.A.Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance. Crofelemer is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Napo EU S.p.A., the majority owned Italian subsidiary of Napo Pharmaceuticals, focuses on expanding crofelemer access in Europe.For more information about Jaguar, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo EU, visit www.napoeu.com.About Mytesi®Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not con...